Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
3665 3750 3601 3609 3580 Last
1961900 2693700 3226600 3358300 3611800 Volume
-0.24% +2.32% -3.97% +0.22% -0.80% Change
Financials
Sales 2021 959 B 9 237 M 9 237 M
Net income 2021 57 094 M 550 M 550 M
Net cash position 2021 666 B 6 414 M 6 414 M
P/E ratio 2021 121x
Yield 2021 0,76%
Sales 2022 1 007 B 9 701 M 9 701 M
Net income 2022 80 256 M 773 M 773 M
Net cash position 2022 698 B 6 723 M 6 723 M
P/E ratio 2022 87,2x
Yield 2022 0,73%
Capitalization 6 935 B 66 815 M 66 810 M
EV / Sales 2021 6,54x
EV / Sales 2022 6,19x
Nbr of Employees 15 348
Free-Float 90,4%
More Financials
Company
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are... 
Sector
Pharmaceuticals
Calendar
01/29 | 05:30amErgebnisveröffentlichung
More about the company
Notations Surperformance© of Daiichi Sankyo Company, Limited
Trading Rating : Investor Rating :
More Ratings
All news about DAIICHI SANKYO COMPANY, LIMITED
01/20AstraZeneca Secures Conditional Approval for Enhertu as Monotherapy for Breas..
MT
01/20AstraZeneca's Enhertu Secures EU Approval to Treat Metastatic Breast Cancer
MT
01/20Nikkei falls on profit-booking as boost from Yellen call fades
RE
01/19Nikkei weakens from early gains as boost from Yellen runs out of gas
RE
01/18DAIICHI SANKYO : Enhertu approved in the US for the treatment of patients with p..
AQ
01/18AstraZeneca's Enhertu Treatment for Metastatic Gastric Cancer Gains Approval ..
MT
01/18PRESS RELEASE : ViGeneron announces research collaboration with Daiichi Sankyo t..
DJ
01/12DAIICHI SANKYO : AstraZeneca to showcase transformative data across diverse pipe..
AQ
01/07As Olympics loom, Japanese approval of Moderna's COVID-19 vaccine unlikely ti..
RE
01/07As Olympics loom, Japanese approval of Moderna's COVID-19 vaccine unlikely ti..
RE
01/05DAIICHI SANKYO : Pays $390 Million in Share Buyback
MT
01/04Japan stocks start year in red as Tokyo braces for state of emergency
RE
01/03Japanese shares fall as PM Suga considers state of emergency for Tokyo
RE
2020Japan shares end near three-decade high after Trump signs stimulus bill
RE
2020Japan stocks end higher on gains in drugmakers, tech stocks
RE
More news
News in other languages on DAIICHI SANKYO COMPANY, LIMITED
2020TOKYO STOCK EXCHANGE : Borsa Tokyo in rialzo su guadagni comparto farmaceutico, ..
2020TOKYO STOCK EXCHANGE : Borsa Tokyo, Nikkei chiude in rialzo su scia Wall Street,..
2020TOKYO STOCK EXCHANGE : Borsa Tokyo, vicina massimi 29 anni e mezzo su notizie va..
2020TOKYO STOCK EXCHANGE : Borsa Tokyo chiude in ribasso dopo allarme virus massimo ..
2020Atomreaktor in Japan darf wieder ans Netz
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | 4568 | JP3475350009 | MarketScreener
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 3 627,27 JPY
Last Close Price 3 580,00 JPY
Spread / Highest target 24,3%
Spread / Average Target 1,32%
Spread / Lowest Target -16,2%
EPS Revisions
Managers and Directors
NameTitle
Sunao Manabe President, CEO & Representative Director
Toshiaki Sai CFO, Representative Director & Executive VP
Wataru Takasaki Executive Officer, GM-Research & Development
Noritaka Uji Independent Outside Director
Satoru Kimura Director & General Manager-Pharmaceutical Sales
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED1.27%66 704
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159